Phase 2 Study of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain (REOLYSIN) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2015
At a glance
- Drugs Pelareorep (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Oncolytics Biotech
- 28 Dec 2015 Results published in the Cancer
- 10 Sep 2015 Planned End Date changed from 1 Sep 2015 to 1 Oct 2015 as reported by ClinicalTrials.gov.
- 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.